NAVB vs. TSLA

In the year-to-date period, NAVB achieves a 900.00% return, which is significantly higher than TSLA's 0.19% return. Over the past 10 years, NAVB has underperformed TSLA with an annualized return of -64.79%, while TSLA has yielded a comparatively higher 39.42% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Navidea Biopharmaceuticals, Inc. (NAVB) and Tesla, Inc. (TSLA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NAVB Sharpe Ratio is -0.09, which is lower than the TSLA Sharpe Ratio of 1.75. The chart below compares the historical Sharpe Ratios of NAVB and TSLA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither NAVB nor TSLA has paid dividends to shareholders.

The maximum NAVB drawdown since its inception was -100.00%, which is greater than TSLA's maximum drawdown of -73.63%. Use the drawdown chart below to compare losses from any high point for NAVB and TSLA. For additional features, visit the drawdowns tool.

Navidea Biopharmaceuticals, Inc. (NAVB) has a higher volatility of 230.26% compared to Tesla, Inc. (TSLA) at 16.04%. This indicates that NAVB's price experiences larger fluctuations and is considered to be riskier than TSLA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Navidea Biopharmaceuticals, Inc. and Tesla, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.